Don't Jump to DOACs First-Line for Cancer-Related VTE

September 2017

We're getting questions about whether to use a direct oral anticoagulant (DOAC) in patients with cancer-associated thromboembolism.

The role of DOACs (apixaban, rivaroxaban, etc) is expanding. Chest guidelines now favor these meds for most patients with venous thromboembolism (VTE)...deep vein thrombosis or pulmonary embolism.

But don't jump to a DOAC first-line to treat or prevent recurrent VTE in cancer patients...due to limited efficacy and safety data.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote